AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

Claim 1 (Currently Amended): A pharmaceutical composition for the treatment of an HIV infection in a host, comprising an effective amount of a β-D-1,3-dioxolanyl purine of the formula:



or its pharmaceutically acceptable salt, wherein

R is H, OH, Cl, NH_2 or NR^1R^2;

R^1 and R^2 are independently hydrogen, alkyl or cycloalkyl; and

R^3 is H, alkyl, aryl, acyl, phosphate, monophosphate, diphosphate, triphosphate, a stabilized phosphate moiety, a phospholipid, or an ether lipid;

in combination with at least one inosine monophosphate dehydrogenase (IMPDH) inhibitor selected from the group consisting of mycophenolic acid and ribavirin or a pharmaceutically acceptable salt or ester thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 2 (Original): The composition of claim 1, wherein the β-D-1,3-dioxolanyl purine is (-)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]-adenine (DAPD).

Claim 3 (Original): The composition of claim 1, wherein the β-D-1,3-dioxolanyl purine is (-)-(2R,4R)-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]-guanine (DXG).

Claim 4 (canceled)

Claim 5 (Currently Amended): The composition of claim 1 [[4]], wherein the IMPDH inhibitor is mycophenolic acid.

Claim 6 (Currently Amended): The composition of claim 1 [[4]], wherein the IMPDH inhibitor is ribavirin.

Claim 7 (Currently Amended): The composition of one of claims 1-3 ~~1-6~~, wherein the β-D-1,3-dioxolanyl purine is enantiomerically enriched.

Claim 8 (Original): The composition of claim 1 in a pharmaceutically acceptable carrier suitable for oral delivery.

Claim 9 (Original): The composition of claim 1 in a pharmaceutically acceptable carrier suitable for intravenous delivery.

Claim 10 (Original): The composition of claim 1 in a pharmaceutically acceptable carrier suitable for parenteral delivery.

Claim 11 (Original): The composition of claim 1 in a pharmaceutically acceptable carrier suitable for topical delivery.

Claim 12 (Original): The composition of claim 1 in a pharmaceutically acceptable carrier suitable for systemic delivery.

Claim 13 (Currently Amended): A method for the treatment of a drug resistant strain of HIV infection in a host in need thereof, comprising administering an effective amount of a β-D-1,3-dioxolanyl purine of the formula:



or its pharmaceutically acceptable salt, wherein

R is H, OH, Cl, NH_2 or NR^1R^2;

R^1 and R^2 are independently hydrogen, alkyl or cycloalkyl; and

R^3 is H, alkyl, aryl, acyl, phosphate, monophosphate, diphosphate, triphosphate, a stabilized phosphate moiety, a phospholipid, or an ether lipid;

in combination with at least one inosine monophosphate dehydrogenase (IMPDH) inhibitor selected from the group consisting of mycophenolic acid and ribavirin or a pharmaceutically acceptable salt or ester thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 14 (Original): The method of claim 13, wherein the β-D-1,3-dioxolanyl purine is (-)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]-adenine (DAPD).

Claim 15 (Original): The method of claim 13, wherein the β-D-1,3-dioxolanyl purine is (-)-(2R,4R)-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]-guanine (DXG).

Claim 16 (Canceled)

Claim 17 (Currently Amended): The method of claim 13 ~~16~~, wherein the IMPDH inhibitor is mycophenolic acid.

Claim 18 (Currently Amended): The method of claim 13 ~~16~~, wherein the IMPDH inhibitor is ribavirin.

Claim 19 (Currently Amended): The method of claim 13 ~~16~~, wherein the HIV infection is resistant to DAPD and/or DXG.

Claim 20 (Currently Amended): The method of any one of claims 13-15 or 17-19 ~~13-19~~, wherein the host is a human.

Claim 21 (Currently Amended): A method for the treatment of HIV infection in a host in need thereof, comprising administering an effective amount of a β-D-1,3-dioxolanyl purine of the formula:



or its pharmaceutically acceptable salt, wherein

or its pharmaceutically acceptable salt, wherein

R is H, OH, Cl, NH_2 or NR^1R^2;

R^1 and R^2 are independently hydrogen, alkyl or cycloalkyl; and

R^3 is H, alkyl, aryl, acyl, phosphate, monophosphate, diphosphate, triphosphate, a stabilized phosphate moiety, a phospholipid, or an ether lipid;

in combination with at least one inosine monophosphate dehydrogenase (IMPDH) inhibitor selected from the group consisting of mycophenolic acid and ribavirin or a pharmaceutically acceptable salt or ester thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 22 (Original): The method of claim 21, wherein the β-D-1,3-dioxolanyl purine is (-)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]-adenine (DAPD).

Claim 23 (Original): The method of claim 21, wherein the β-D-1,3-dioxolanyl purine is (-)-(2R,4R)-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]-guanine (DXG).

Claim 24 (Canceled)

Claim 25 (Currently Amended): The method of claim 21 ~~24~~, wherein the IMPDH inhibitor is mycophenolic acid.

Claim 26 (Currently Amended): The method of claim 21 ~~24~~, wherein the IMPDH inhibitor is ribavirin.

Claim 27 (Currently Amended): The method of any one of claims 21-23 or 25-26 ~~21-26~~, wherein the host is a human.

Claim 28 (Previously Presented): The method of claim 13 or 21, wherein the β-D-1,3-dioxolanyl purine is enantiomerically enriched.

Claim 29 (Previously Presented): The method of claim 28, wherein the β-D-1,3-dioxolanyl purine ~~that enantiomerically enriched~~ is DAPD or DXG.

Claim 30 (Previously Presented): The method of claim 13, wherein the drug-resistant virus is resistant to a β-D-1,3-dioxolanyl purine resistant virus.